Skip to main content

Table 1 Participant demographics, comorbidities and laboratory values

From: Effect of omega-three supplementation on serum urate and gout flares in people with gout; a pilot randomized trial

  Omega 3 (n = 19) Control (n = 21) Total (n = 40)
Male 14 (73.7%) 20 (95.2%) 34 (85.0%)
NZ European 13 (68.4%) 18 (85.7%) 31 (77.5%)
Age years) 63.3 (12.3) 59.3 (14.7) 61.2 (13.6)
Weight kg 89.0 (22.3) 91.4 (19.2) 88.8 (20.6)
BMI kg/m2 30.3 (6.5) 29.7 (5.2) 30.0 (5.8)
Hypertension 7 (36.8%) 9 (42.9%) 16 (40%)
Hyperlipidaemia 5 (26.3%) 5 (23.8%) 10 (25%)
Type 2 diabetes 3 (15.8%) 1 (4.8%) 5 (10%)
Ischaemic heart disease 0 (0) 2 (9.5%) 2 (5%)
Serum urate mmol/l 0.44 (0.08) 0.46 (0.08) 0.45 (0.08)
eGFR (ml/min/1.73m2) 68.5 (15.6) 69.7 (18.9) 69.1 (17.2)
Cholesterol (mmol/l) 5.4 (1.0) 5.2 (1.1) 5.3 (1.0)
Triglycerides (mmol/l) 2.1 (0.8) 2.4 (1.3) 2.3 (1.1)
HDL (mmol/l) 1.3 (0.3) 1.2 (0.3) 1.2 (0.3)
LDL (mmol/l) 3.1 (1.0) 3.0 (0.9) 3.0 (0.9)
Cholesterol (total/LDL) 4.3 (1.1) 4.5 (1.4) 4.4 (1.3)
Total red cell omega 3% 4.6 (1.2) 4.4 (0.9) 4.5 (1.0)
20:5n-3 (EPA)% 0.8 (0.3) 0.8 (0.3) 0.8 (0.3)
22:6n-3 (DHA)% 2.1 (0.5) 1.9 (0.4) 2.0 (0.5)
HbA1C (mmol/mol) 41.4 (16.2) 35.8 (11.1) 38.5 (13.9)
On allopurinol 8 (42.0%) 9 (43.0%) 17 (42.5%)
Serum Oxypurinol (µmol/l) 69.3 (38.4) (n = 8) 42.8 (28.6) (n = 9) 55.3 (35.2)
Tophi present 4 (21.1%) 3 (14.3) 7 (17.5%)
Flare prophylaxis 4 (21.1%) 2 (9.5%) 6 (15%)
  1. Data are presented as mean (SD) or n(%) unless otherwise stated
  2. NZ New Zealand, BMI body mass index, kg kilogram, eGFR estimated glomerular filtration rate, HDL high density lipoprotein, LDL low density lipoprotein, EPA eicosapentaenoic acid and DHA docosahexaenoic acid